Daniel J Safer1, Chadi A Calarge, Alan M Safer. 1. Departments of Psychiatry and Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. dsafer@jhmi.edu
Abstract
OBJECTIVE: This study aimed to: document the extent of the reduction of serum prolactin (PRL) levels induced by aripiprazole (ARI) treatment in children and adolescents, compare this effect by age group, and shed light on this phenomenon. METHODS: PRL serum levels in unmedicated subjects were compared to those in subjects treated with aripiprazole to calculate the rate of subnormal PRL levels during aripiprazole treatment. Next, a literature search was performed to better understand the effects of dopaminergic drugs on PRL levels by age group. RESULTS: Sixty percent of those treated with aripiprazole exhibited subnormal PRL serum levels versus 8% of unmedicated subjects. The rate of PRL subnormality in response to aripiprazole was half as frequent in adolescents and was minimal in adults. The drug-induced reduction of PRL serum levels became more prominent with increasing doses of aripiprazole and with an increased treatment duration. CONCLUSIONS: With the increasing use of aripiprazole in the United States population, it is important that future research be conducted to explore the potential sequelae of subnormal PRL serum levels in children and adolescents.
OBJECTIVE: This study aimed to: document the extent of the reduction of serum prolactin (PRL) levels induced by aripiprazole (ARI) treatment in children and adolescents, compare this effect by age group, and shed light on this phenomenon. METHODS:PRL serum levels in unmedicated subjects were compared to those in subjects treated with aripiprazole to calculate the rate of subnormal PRL levels during aripiprazole treatment. Next, a literature search was performed to better understand the effects of dopaminergic drugs on PRL levels by age group. RESULTS: Sixty percent of those treated with aripiprazole exhibited subnormal PRL serum levels versus 8% of unmedicated subjects. The rate of PRL subnormality in response to aripiprazole was half as frequent in adolescents and was minimal in adults. The drug-induced reduction of PRL serum levels became more prominent with increasing doses of aripiprazole and with an increased treatment duration. CONCLUSIONS: With the increasing use of aripiprazole in the United States population, it is important that future research be conducted to explore the potential sequelae of subnormal PRL serum levels in children and adolescents.
Authors: Barbara Geller; Joan L Luby; Paramjit Joshi; Karen Dineen Wagner; Graham Emslie; John T Walkup; David A Axelson; Kristine Bolhofner; Adelaide Robb; Dwight V Wolf; Mark A Riddle; Boris Birmaher; Nasima Nusrat; Neal D Ryan; Benedetto Vitiello; Rebecca Tillman; Philip Lavori Journal: Arch Gen Psychiatry Date: 2012-01-02
Authors: Eduard Vieta; Michel Bourin; Raymond Sanchez; Ronald Marcus; Elyse Stock; Robert McQuade; William Carson; Neveen Abou-Gharbia; Rene Swanink; Taro Iwamoto Journal: Br J Psychiatry Date: 2005-09 Impact factor: 9.319
Authors: Giovanni Corona; Edoardo Mannucci; Emmanuele A Jannini; Francesco Lotti; Valdo Ricca; Matteo Monami; Valentina Boddi; Elisa Bandini; Giancarlo Balercia; Gianni Forti; Mario Maggi Journal: J Sex Med Date: 2009-02-10 Impact factor: 3.802
Authors: Ronald N Marcus; Randall Owen; Lisa Kamen; George Manos; Robert D McQuade; William H Carson; Michael G Aman Journal: J Am Acad Child Adolesc Psychiatry Date: 2009-11 Impact factor: 8.829
Authors: Chadi A Calarge; Stephanie D Ivins; Katherine J Motyl; Amal A Shibli-Rahhal; Michael M Bliziotes; Janet A Schlechte Journal: Ther Adv Psychopharmacol Date: 2013-10
Authors: Judith J G Rath; Marlies E J Deen; Hessel van Houten; Sebastiaan F T M de Bruijn; Joop van Gerven; Dick Mul Journal: Ther Adv Psychopharmacol Date: 2017-04-21